Xi'an Faithful BioTech Co., Ltd. yog muag Tirzepatide Raw Powder. Thov koj xav tiv tauj peb yog tias koj muaj kev xav tau kev yuav khoom.
Xa koj Cov Lus Nug kom paub meej ntxiv, Nyem email:sales4@faithfulbio.com
I. Core Attributes:
Cov yam ntxwv tshuaj thiab kev npaj ntawm Dual - Cov Khoom Siv Lub Hom Phiaj Telpotripeptide yog cov khoom siv hluavtaws uas tsim los ntawm fatty acid- hloov pauv peptide khoom. Chemically, nws yog polypeptide molecule muaj li ntawm 39 amino acids, muaj ib tug C20 fatty acid tail. Cov qauv tshwj xeeb no tso cai rau nws los khi zoo rau albumin, ua kom nws lub sijhawm ua haujlwm ntev hauv vivo. Nws cov mis molecular yog C₂₂₁H₃⁴₄N₆₀O₇₁S, nrog rau qhov hnyav molecular kwv yees li 5100 Da.
Raws li cov khoom lag luam polypeptide, kev npaj ntawm Telpotripeptide yog nyob ntawm siab -precision solid-theem synthesis technology. Cov txheej txheem tseem ceeb suav nrog peb cov kauj ruam tseem ceeb: kev sib sau ua ke ntawm cov amino acid, kev hloov pauv fatty acid, thiab purification. Lub synthesis ntawm nws cov khoom siv tshuaj nquag (API) yuav tsum muaj kev tswj xyuas siab heev ntawm cov tshuaj tiv thaiv ib puag ncig, xav tau kev tswj hwm kub, pH, thiab lub sijhawm tshuaj tiv thaiv kom tsis txhob muaj cov amino acid mismatch. Cov formulation excipients tsuas muaj inert Cheebtsam xws li physiological saline thiab phosphates, ua kom cov khoom muaj kev ruaj ntseg thaum simplifying cov txheej txheem ntau lawm. Tam sim no, Eli Lilly tau tsim cov txheej txheem tsim khoom thoob ntiaj teb, ua tiav ntau dua 99% plasma protein khi los ntawm cov txheej txheem patented synthesis, tso lub hauv paus rau ntev - ua cov khoom xa tuaj.
II. R & D Cov ntsiab lus: Ib xyoo caum ntawm kev tawg los ntawm Lub Hom Phiaj Innovation mus rau Kev Pom Zoo Thoob Ntiaj Teb
The development of telpotetide began in the 2010s, with its core R&D logic stemming from in-depth exploration of metabolic regulation mechanisms. At that time, single-target GLP-1 receptor agonists (such as smegglutide) had proven their value in the field of blood sugar control, but suffered from limited weight loss effects and a single mechanism of action. Eli Lilly's R&D team discovered that GIP (glucose-dependent insulinotropic peptide) receptors and GLP-1 receptors have a synergistic effect in metabolic regulation; activating both receptors could achieve a "1+1>2 "cov nyhuv kho. Lub tswv yim tshiab no tau los ua qhov pib rau kev txhim kho ntawm telpotetide.
2022 tau cim lub ntsiab lus tseem ceeb rau Zepbound: Lub Plaub Hlis, cov ntaub ntawv los ntawm SURMOUNT series ntawm kev sim tshuaj raug tso tawm, lees paub tias nws cov txiaj ntsig zoo tshaj qhov poob phaus piv rau cov khoom uas twb muaj lawm; Thaum Lub Tsib Hlis 13th, nws tau txais kev pom zoo los ntawm FDA hauv Asmeskas, ua lag luam raws li hom npe Mounjaro rau kev tswj glycemic hauv cov neeg mob ntshav qab zib hom 2, ua tiav $ 483 lab hauv cov nyiaj tau los hauv thawj xyoo. Txoj kev loj hlob sai sai hauv 2023. Nyob rau lub Rau Hli, kev tshawb fawb luam tawm hauv *Nature Metabolism* tau lees paub qhov kev tshawb fawb ntawm nws dual -receptor activation mechanism; Thaum Lub Kaum Ib Hlis, FDA tau pom zoo ntxiv nws qhov kev poob phaus, hloov kho lub npe rau Zepbound, ua rau nws thawj cov khoom siv tshuaj kom ua tiav qhov hnyav poob qis dua 20% hauv Phase 3 kev sim tshuaj.
Hauv Suav lag luam, cov txheej txheem kev pom zoo rau Zepbound tau nce ib txhij: ib qho kev qhia tshiab tau xa mus rau kev pom zoo kev lag luam thaum Lub Yim Hli 2023, thiab nws tau txais kev pom zoo los ntawm National Medical Products Administration (NMPA) thaum lub Tsib Hlis 21, 2024. Nyob rau lub Kaum Ob Hlis ntawm tib lub xyoo, muaj feem cuam tshuam txog kev kuaj mob thiab cov kev pabcuam tshuaj muaj nyob rau hauv kev lag luam kev lag luam nrawm nrog {,{3} kev sib txuas ceev platform. Raws li xyoo 2025, nws cov lus qhia nthuav dav kev tshawb fawb tau npog thaj chaw xws li tsis yog - haus dej cawv fatty siab kab mob (NASH), lub plawv tsis ua hauj lwm, thiab obstructive pw tsaug zog apnea, tsim ib tug multi-R&D pipeline.
Xa koj Cov Lus Nug kom paub meej ntxiv, Nyem email:sales4@faithfulbio.com
III. Pharmacological Mechanism: Ib Revolution in Metabolic Regulation Los Ntawm Dual -Receptor Synergistic Action
Lub ntsiab kom zoo dua ntawm telpolide yog nyob rau hauv nws ib txhij ua kom ob leeg GIP thiab GLP-1 incretin receptors, ua tiav cov kev cai metabolic los ntawm triple - txoj kev ua. Cov txheej txheem no sawv cev rau qhov kev ua tiav zoo piv rau cov khoom lag luam ib hom phiaj. Kev tshawb fawb luam tawm nyob rau hauv * Xwm Metabolism * lees paub tias nyob rau hauv tib neeg pancreatic islet hlwb, GIP receptor activation yog ib qho tseem ceeb rau insulin secretion, thaum GLP-1 receptor activation tsom rau kev qab los noj mov. Ua ke, lawv tsim cov txheej txheem metabolic ntau dua.
Ua ntej, hais txog kev tswj cov ntshav qabzib: GLP-1 receptor activation txhawb nqa insulin tso tawm los ntawm pancreatic -cells thaum inhibiting glucagon secretion los ntawm -cells, ua tiav cov ntshav qabzib-tiv thaiv cov ntshav qabzib thiab zam kev pheej hmoo ntawm hypoglycemia. GIP receptor activation ntxiv txhim kho insulin rhiab heev, tshwj xeeb tshaj yog ntxiv dag zog rau cov nyhuv hypoglycemic hauv cov xeev hyperglycemic. Cov ntaub ntawv kho mob qhia tau tias hauv cov neeg mob ntshav qab zib hom 2, telpolide txo glycated hemoglobin (HbA1c) los ntawm 1.6% -2.1%, zoo dua rau cov nyhuv hypoglycemic ntawm smegglutide.
Qhov thib ob, cov txheej txheem ntawm kev poob phaus yog raws li hauv qab no: GLP-1 receptor activation suppresses qab los noj mov thiab qeeb plab hnyuv plab los ntawm kev ua haujlwm ntawm lub hauv nruab nrab lub paj hlwb, yog li txo qis calorie kom tsawg; GIP receptor activation tshwj xeeb nce kev siv hluav taws xob thiab txhawb nqa lipolysis. Hom "bidirectional regulation" no ua rau poob ceeb thawj. Txoj kev tshawb nrhiav SURMOUNT-5 tau pom tias pawg koob tshuaj 15mg tau ua tiav qhov hnyav nruab nrab ntawm 22.8 kg dhau 72 lub lis piam, qhov hnyav poob ntawm 20.2%, uas yog 1.47 npaug ntawm pawg semaglutide (13.7%).
Tsis tas li ntawd, semaglutide muaj kev tiv thaiv kev tiv thaiv ntawm cov kab mob metabolically, txhim kho hepatic steatosis los ntawm kev tswj cov theem ntawm cov kab mob inflammatory thiab txo cov kev pheej hmoo ntawm cov kab mob plawv, muab cov tshuaj pharmacological rau kev nthuav dav nws cov lus qhia.
IV. Cov ntawv thov kev kho mob: Kev tawg nyob rau hauv ntau yam xwm txheej los ntawm kev tswj ntshav qab zib kom poob phaus
Tam sim no, telpotetide cov ntsiab lus tseem ceeb tau tsim "dual{0}} ncej" qauv: Hauv kev kho mob ntshav qab zib hom 2, nws tsim nyog rau cov neeg laus uas muaj kev noj zaub mov tsis zoo thiab kev tswj hwm kev tawm dag zog, tshwj xeeb tshaj yog cov neeg rog rog, ua tiav cov ntshav qab zib ib txhij thiab tswj qhov hnyav; hauv kev kho mob rog rog, nws yog thawj cov khoom siv tshuaj kom ua tiav "qhov hnyav poob ntau dua 20%" rau cov neeg mob uas muaj BMI Ntau dua lossis sib npaug ntawm 30 lossis BMI Ntau dua lossis sib npaug rau 27 thiab rog rog - cuam tshuam txog kev mob.
Cov ntaub ntawv thov kev kho mob qhia tau tias muaj txiaj ntsig zoo: Hauv cov neeg mob ntshav qab zib, koob tshuaj 5mg kho rau 72 lub lis piam ua rau 15.7% poob phaus, hais txog kev tswj ntshav qab zib thiab kev xav tau kev poob phaus; Hauv cov neeg mob uas muaj kev rog yooj yim, 15mg koob tshuaj pab pawg pom qhov nruab nrab lub duav ncig ntawm qhov txo qis ntawm 18.4cm, deb tshaj li 13.0cm txo qis hauv pawg smegglutide, thiab 64.6% ntawm cov neeg mob ua tiav qhov poob phaus ntau dua lossis sib npaug li 15%, 1.6 npaug ntawm pawg tswj hwm (40.1%). Thaum Lub Kaum Ob Hlis 2024, nws cov lus qhia rau kev kho mob ntawm obstructive pw tsaug zog apnea tau pom zoo, ua nws thawj GLP-1 khoom rau tus kab mob no, ntxiv nthuav nws cov nqi kho mob.
Hais txog kev siv cov lus qhia, telpotetide yog siv los ntawm kev txhaj tshuaj subcutaneous ib zaug ib lub lim tiam. Thawj koob tshuaj feem ntau yog 2.5 mg, maj mam hloov mus rau lub hom phiaj koob tshuaj raws li kev kam rau siab, nrog rau qhov siab tshaj plaws koob tshuaj tsis pub tshaj 15 mg. Cov kev phiv tshwm sim feem ntau suav nrog kev mob plab hnyuv xws li xeev siab, ntuav, thiab raws plab, uas feem ntau tshwm sim thaum pib kho thiab txo qis nrog kev kho mob. Qhov tshwm sim ntawm cov kev mob tshwm sim yog me ntsis siab dua nyob rau hauv siab - pab pawg koob tshuaj, tab sis tag nrho cov tolerability yog zoo dua li ib txwm yuag - cov khoom poob. Thaum kho, nws yog ib qho tsim nyog yuav tsum tsis txhob siv cov tshuaj insulin lossis lwm yam khoom siv hypoglycemic los tiv thaiv kev pheej hmoo ntawm hypoglycemia.
V. Kev Lag Luam Status: Lub Duopoly Dominated los ntawm Pua pua -Billion-Dollar Market
Kev ua lag luam thoob ntiaj teb nthuav tawm kev sib tw duopoly ntawm Eli Lilly thiab Novo Nordisk. Eli Lilly, leveraging cov txiaj ntsig zoo ntawm nws cov telpotetide, tau txais kev lag luam sai sai. Raws li lub quarter thib peb ntawm 2025, nws feem ntawm GLP-1 cov tshuaj hauv Teb Chaws Asmeskas tau txog 57.9%, tshaj semaglutide (41.7%) thawj zaug. Hauv nws thawj xyoo ntawm kev ua lag luam, telpotetide tau tsim $ 483 lab hauv cov nyiaj tau los hauv 2022, thiab los ntawm thawj peb lub hlis twg ntawm 2025, nws cov nyiaj tau los peb lub hlis twg tau txog $ 6.15 billion. Thaum tseem qis dua semaglutide tus $ 8.011 billion, nws txoj kev loj hlob muaj zog dua.
Hais txog cov txheej txheem tsim khoom, Eli Lilly tau tsim lub ntiaj teb kev tsim khoom lag luam nyob hauv Europe thiab Asmeskas, ntxiv los ntawm Asia - cheeb tsam Pacific. Hauv Suav teb, nws tau siv cov kev pabcuam kho mob sai heev los ntawm cov qauv kev sib koom tes. Thaum Lub Kaum Ob Hlis 2024, ntau lub tsev lag luam e- kev lag luam platform tau qhib telpotetide kev kho mob thiab cov tshuaj kho mob, ua kom muaj kev nkag mus rau kev lag luam sai. Hais txog tus nqi thiab tus nqi, nws cov nqi kho mob txhua hli yog kwv yees li RMB 7,700, 20% qis dua semaglutide, ua rau nws tus nqi kom zoo dua qhov kev txhawb nqa tseem ceeb rau kev nthuav dav kev lag luam.
Kev ua lag luam hauv tsev nthuav tawm tus qauv ntawm "kev coj noj coj ua yeeb yam qub + kev siv tshuaj ntau dua- nce." Hengrui Medicine's GIP/GLP-1 dual{10}}target agonist HRS9531 tau ua tiav Phase III kev sim tshuaj, qhia qhov hnyav poob ntawm 19.2% dhau 48 lub lis piam hauv pawg koob tshuaj 6mg, thiab nws daim ntawv thov kev lag luam tau txais. Cov khoom zoo sib xws los ntawm cov tuam txhab xws li Innovent Biologics thiab CSPC Pharmaceutical Group kuj tau nkag mus lig- cov kev sim tshuaj ntsuam xyuas theem, tsom mus rau ob lub hom phiaj ua ke xws li GLP-1 / GIP thiab GLP-1 / GCG. 3-5 xyoos tom ntej no yuav pom qhov siab tshaj plaws hauv kev sib tw generic.
Hais txog kev lag luam loj, GLP thoob ntiaj teb-1 kev lag luam tshuaj tau txog $ 51.8 nphom hauv 2024, ib xyoos - nce xyoo ntawm 42%, thiab kwv yees kom tshaj $ 60 nphom hauv 2025 thiab ncav cuag ntau dua $ 80 nphom los ntawm 2030. Ntawm lawv, telpotetide, nrog rau nws lub peev xwm rau kev nthuav dav txog $ 4 billion hauv kev lag luam, 2028.
VI. Txoj Cai Tswjfwm: Kev tswj hwm thoob ntiaj teb sib txawv thiab kev lag luam nkag mus tau zoo
Cov koom haum tswj hwm hauv ntau lub tebchaws tau tsim cov kev cai sib txawv ntawm kev txheeb xyuas qhov ua tau zoo thiab kev tswj hwm kev pheej hmoo ntawm telpotetide. US FDA tau txais ib qho "kev ceev nrawm + kev tshuaj xyuas qhov tseem ceeb" tus qauv, sai sai pom zoo nws ob qho kev qhia txog kev tswj ntshav qab zib thiab kev poob phaus raws li cov ntaub ntawv tseem ceeb los ntawm SURMOUNT series sim, tab sis xav kom Eli Lilly ua ntev - lub sij hawm saib xyuas kev nyab xeeb ntawm lub plawv. EU EMA tsom ntau dua rau cov lus ceeb toom txog kev pheej hmoo ntawm kev mob plab hnyuv thaum lub sijhawm pom zoo, xav kom cov khoom qhia kom meej meej cov ntsiab lus rau kev hloov tshuaj.
Tuam Tshoj cov koom haum tswj hwm tau txais kev pom zoo "tus nqi kho mob- taw qhia" txoj hauv kev, pom zoo nws txoj kev lag luam hauv lub Tsib Hlis 2024 raws li cov ntaub ntawv thoob ntiaj teb multicenter, thaum xav tau ntxiv ntev - cov ntaub ntawv kev nyab xeeb rau cov pej xeem Suav. Tam sim no, telpotetide tsis suav nrog hauv phau ntawv pov hwm kho mob hauv tebchaws, ua rau kev sib tham txog kev pov hwm kho mob ua kom pom tseeb ntawm kev ua lag luam. Nws cia siab tias nws tus nqi yuav siv cov qauv kev pov hwm kho mob ntawm semaglutide, kev sib pauv tus nqi rau kev lag luam ntau dua.
Kev tswj hwm kev tsom xam yog tsom mus rau peb yam: ua ntej, kev nyab xeeb ntawm kev siv sijhawm ntev -, tshwj xeeb tshaj yog muaj feem cuam tshuam rau cov thyroid C- cov qog nqaij hlav, uas EU tau tshaj tawm cov lus ceeb toom txaus ntshai; Thib ob, kev tswj hwm kev tsim txom los tiv thaiv kev siv tsis raug cai los ntawm pawg tsis yog- qhia; thiab qhov thib peb, cov saw hlau ruaj ntseg, raws li Eli Lilly tau ntsib luv luv -cov khoom tsis txaus vim qhov kev thov nce ntxiv, thiab cov koom haum tswj hwm tau xav kom nws ntxiv dag zog rau nws cov peev txheej tsim khoom.
VII. Txoj Kev Loj Hlob: Ib Txoj Kev Tsim Kho Tshiab ntawm Lub Sijhawm thiab Kev Sib Tw
Txoj kev loj hlob ntawm telpotetide ntsib ntau lub sijhawm. Expanding indications yog lub hauv paus loj hlob engine. Tam sim no, nws cov kev tshawb fawb soj ntsuam hauv cov cheeb tsam xws li NASH, lub plawv tsis ua hauj lwm, thiab cov kab mob hauv lub raum tau ua tiav zoo, thiab kev pom zoo ua tiav yuav qhib kev lag luam muaj nqis ntau pua lab. Formulation innovation kuj yuav txhim kho qhov yooj yim ntawm cov tshuaj. Eli Lilly twb tau pib txhim kho cov qauv ntawm qhov ncauj los daws cov teeb meem kev ua raws li kev tswj hwm kev txhaj tshuaj, thaum kev tshawb nrhiav ntev - cov qauv ua yeeb yam yuav tsum txuas ntxiv lub voj voog koob tshuaj ib zaug txhua ob lub lis piam.
Cov kev sib tw tseem ceeb sib npaug. Patent teeb meem yuav maj mam tawg, nrog rau nws cov patents tseem ceeb yuav tsum tas sij hawm tom qab 2030. Cov tuam txhab tshuaj generic hauv tsev tau npaj ua ntej, thiab kev sib tw ua lag luam yav tom ntej yuav hloov ntawm "kev sib tw ua tau zoo" mus rau "kev tswj hwm tus nqi." Qhov kev xav tau rau kev ua kom zoo dua qub yog qhov ceev; gastrointestinal cov tshuaj tiv thaiv tseem yog ib qho tseem ceeb cuam tshuam rau kev ua raws cai. Tom ntej no - cov khoom tsim tsim yuav tsum muaj kev ua tau zoo thaum txo qis qhov tshwm sim ntawm qhov tsis zoo tshwm sim. Tsis tas li ntawd, kev sib tw hauv GLP-1 thaj tsam tau nce zuj zus. Txawm hais tias cov tuam txhab xws li AstraZeneca thiab Pfizer tau txiav cov khoom tsim tawm, qhov nrawm nrawm los ntawm cov tuam txhab hauv tebchaws xws li Innovent thiab Hengrui yuav rov tsim kho thaj chaw ua lag luam.
Cov kev taw qhia ntawm kev txhim kho thev naus laus zis tau pom qhov txawv txav: ntau- lub hom phiaj sib txuas tau dhau los ua qhov tseem ceeb ntawm kev tshawb fawb thiab kev loj hlob, xws li GLP-1/GIP/GCG peb-lub hom phiaj agonists uas tau nkag mus rau theem pib ntawm kev sim tshuaj; daim ntawv thov ntawm cov tshuaj precision yog nrawm, thiab cov pej xeem tsim nyog tshaj plaws yog tshuaj xyuas los ntawm kev tshuaj ntsuam gene kom ua tiav "kev xa tshuaj tus kheej"; Kev siv tshuaj xa khoom thev naus laus zis txuas ntxiv mus, thiab cov ntawv siv tshuaj tshiab xws li microsphere formulations thiab transdermal thaj ua rau thaj yog nyob rau hauv kev txhim kho.
Xaus
Lub advent ntawm telpolide tsis yog tsuas yog ib tug technological breakthrough nyob rau hauv kev kho mob ntawm metabolic kab mob, tab sis kuj yog ib tug paradigm hloov nyob rau hauv kev tshawb fawb thiab kev loj hlob ntawm peptide khoom. Nws dual - lub hom phiaj kev sib koom ua ke ua kom muaj txiaj ntsig kev tshawb fawb ntawm ntau- kev tswj hwm kev tswj hwm, ua rau cov tuam txhab tshuaj lag luam thoob ntiaj teb hloov pauv los ntawm "ib zaug- lub hom phiaj hauv - kev tshawb fawb tob" mus rau "ntau- lub hom phiaj sib koom ua ke" R & D mus kom ze. Tau ntsib kev lag luam muaj nqis ntau pua lab nyiaj, telpolide yuav tsum tau hais txog cov kev mob tshwm sim, kev ua raws cai, thiab cov teeb meem raug nqi thaum tuav nws cov txiaj ntsig zoo. Nyob rau hauv lub neej yav tom ntej, nrog kev nthuav dav ntawm cov lus qhia, kev tsim kho tshiab hauv kev tsim cov thev naus laus zis, thiab kev siv cov ntawv pov hwm kho mob maj mam, telpolide xav tias yuav dhau los ua "cov khoom lag luam" hauv cov khoom lag luam metabolic, coj kev kho tshiab kev cia siab rau ntau lab tus neeg mob uas muaj kab mob metabolic thoob ntiaj teb, thaum tib lub sijhawm propelling Suav cov tuam txhab tshuaj tshiab los ntawm "LPleader" 1.
Raws li tus neeg muab kev pabcuam zoo tshaj plaws Tirzepatide CAS 654671-78-0, Xi'an Faithful BioTech Co., Ltd. leverages xeev- ntawm- the-art technology production and rigorous quality assurance to as international pharmaceutical requirements. Peb txoj kev mob siab rau kev ua tau zoo tshaj plaws, tus nqi tsim nyog, thiab kev txhawb nqa kev tsim kho tau ua rau peb nyiam koom tes rau cov kws kho mob thiab cov kws tshawb fawb thoob ntiaj teb. Txhawm rau kom tau txais cov ncauj lus qhia ntxaws ntxaws thiab daim ntawv thov kev taw qhia rau peb Tirzepatide Powder, hu rau peb pab neeg ua haujlwm ntawmsales4@faithfulbio.comthiab tshawb xyuas seb peb cov khoom tuaj yeem txhim kho koj cov khoom tsim li cas.